Trial Profile
A Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention (CHAMPION PHOENIX)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Jan 2022
Price :
$35
*
At a glance
- Drugs Cangrelor (Primary) ; Clopidogrel
- Indications Acute coronary syndromes; Angina pectoris; Atherosclerosis; Myocardial infarction; Stent thrombosis
- Focus Registrational; Therapeutic Use
- Acronyms CHAMPION; CHAMPION-PHOENIX; PHOENIX
- Sponsors The Medicines Company
- 25 Jan 2022 According to Chiesi Farmaceutici media release, results of post hoc analysis of this trial published in Circulation: Cardiovascular Interventions, a journal of the American Heart Association,
- 25 Jan 2022 Results of post hoc analysis of this trial published in the Chiesi Farmaceutici Media Release
- 29 Jun 2019 Results evaluating the efficacy and safety of cangrelor compared with clopidogrel among patients in the CHAMPION PHOENIX trial published in the Clinical Cardiology